SynthesisAnnals of hematology2025
Efficacy of radiotherapy in primary mediastinal diffuse large B-cell lymphoma: a systematic review and meta-analysis of 1,392 patients.
Synthesis in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Primary mediastinal B-cell lymphoma (PMBCL) patients who achieve a complete response (CR) following first-line immunochemotherapy tend to have favorable outcomes, even without subsequent radiotherapy (RT). However, it remains unclear whether the survival of patients who do not achieve CR after first-line therapy and subsequently receive radiotherapy is comparable to that of CR patients who undergo observation alone. To address this gap, we conducted a systematic review and meta-analysis to compare progression-free survival (PFS) and overall survival (OS) between CR patients who forgo radiotherapy and non-CR patients who receive consolidative radiotherapy. Additionally, we examined potential influencing factors to provide evidence-based guidance for clinical treatment strategies. A comprehensive search of multiple databases (PubMed, EMBASE, and Cochrane Library) was conducted for the period from January 1, 2012, to September 1, 2024. Using predefined keywords and screening procedures, 15 studies were ultimately included. The primary endpoint was PFS, with OS as a secondary endpoint. Subgroup analyses were performed based on chemotherapy regimens. This systematic review and meta-analysis of 15 studies demonstrated that consolidative radiotherapy significantly improves PFS in patients with partial remission (PR) after first-line immunochemotherapy, with an overall risk ratio (RR) of 1.11 (95% confidence interval [CI]: 1.05-1.16). For OS, the RR was 1.04 (95% CI: 0.97-1.12), crossing the line of no effect, which suggests that consolidative radiotherapy does not have a statistically significant impact on OS. Consolidative radiotherapy improves PFS in patients with PMBCL, but its effect on OS is not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.